Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

MACROGENICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against MacroGenics, Inc. - MGNX

MGNX

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have untilSeptember 24, 2024 to file lead plaintiff applications in a securities class action lawsuit against MacroGenics, Inc. (or the “Company”) (NasdaqGS: MGNX), if they purchased the Company’s shares or sold the Company’s puts between March 7, 2024 to May 9, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Maryland.

What You May Do

If you purchased or sold MacroGenics as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-mgnx/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by September 24, 2024.

About the Lawsuit

MacroGenics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On May 9, 2024, the Company disclosed that five patients had died in a study of the company’s cancer drug, vobra duo, two of which it had deemed unrelated to the drug, and that “[t]he latter three deaths are being investigated, as follow-up is incomplete on this ongoing trial.”

On this news, the price of MacroGenics’ shares fell from $14.67 per share on May 9, 2024, to $3.31 per share on May 10, 2024.

The case is Crain v. MacroGenics, Inc., et al., No. 24-cv-02184.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today